Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 126Melanoma 92Neoplasms 82Colorectal Neoplasms 62Squamous Cell Carcinoma of Head and Neck 61Neoplasm Metastasis 59Triple Negative Breast Neoplasms 51Carcinoma, Renal Cell 47Breast Neoplasms 39Lung Neoplasms 37Ovarian Neoplasms 32Pancreatic Neoplasms 30Head and Neck Neoplasms 29Stomach Neoplasms 28Urinary Bladder Neoplasms 26Carcinoma, Transitional Cell 26Endometrial Neoplasms 24Parkinson Disease 4, Autosomal Dominant Lewy Body 23Uterine Cervical Neoplasms 21Carcinoma, Hepatocellular 18Recurrence 15Esophageal Neoplasms 15Prostatic Neoplasms 14Lymphoma 14Small Cell Lung Carcinoma 12Carcinoma, Squamous Cell 12Kidney Neoplasms 11Cholangiocarcinoma 11Advanced Solid Tumor 11Solid Tumor 10

Interventions

Temozolomide 27Irinotecan 8Filgrastim 8Carmustine 7Carboplatin 7Surgical Procedures, Operative 6O(6)-benzylguanine 6Flucytosine 6sargramostim 4Vorinostat 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4vocimagene amiretrorepvec 3lonafarnib 3Radiosurgery 3Lenalidomide 3Imatinib Mesylate 3Genetic Therapy 3Erlotinib Hydrochloride 3Cyclophosphamide 3Bortezomib 3temsirolimus 2cediranib 2aldesleukin 2Vincristine 2Vinblastine 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Oligodendroglioma × pembrolizumab × Clear all
NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Servier

Phase 1 Active not recruiting
60 enrolled
CNS

Astrocytoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡